Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
152 hedge funds and large institutions have $1.72B invested in Sage Therapeutics in 2016 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 27 closing their positions.
89% more capital invested
Capital invested by funds: $911M → $1.72B (+$810M)
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
33% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 27
14% more call options, than puts
Call options by funds: $24.9M | Put options by funds: $21.8M
6% more funds holding
Funds holding: 144 → 152 (+8)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$46.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.9M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$37.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$22M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$9.91M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$9.77M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$8.46M |
| 5 |
FHAM
Folger Hill Asset Management
New York
|
-$7.31M |
SAGE Hedge Fund Activity: Q3 2016 in Review
152 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2016, worth a combined $1.72B — up 89% from $911M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SAGE positions and 27 closed out — a net gain of 9 holders — while 59 added to existing stakes and 41 trimmed.
The largest buyer was OppenheimerFunds, adding an estimated $46.6M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22M sold.
- 152 institutional investors held Sage Therapeutics (SAGE) as of Q3 2016, up from 144 in Q2 2016.
- Funds reported $1.72B of Sage Therapeutics stock for Q3 2016, up 89% quarter-over-quarter.
- 36 funds opened new Sage Therapeutics positions in Q3 2016 and 27 closed out, a net change of +9 holders.
- The largest Sage Therapeutics buyer in Q3 2016 was OppenheimerFunds, an estimated $46.6M added.
- The largest Sage Therapeutics seller in Q3 2016 was Cormorant Asset Management, an estimated $22M sold.
Based on aggregated 13F filings for Q3 2016.